UAT | AEM3-605 | Press Listing displaying OOPS error-SCWR-17301

News Release

• MilliporeSigma announces a non-binding MoU with Mycenax Biotech to optimize bioprocessing production of life-changing biological therapies
  
• Integrates company‘s BioContinuum™ Platform in Mycenax’s Contract Development and Manufacturing Services (CDMO) for maximum safety, control, transparency, and repeatability
  
• Collaboration aims to enhance process intensification, advance towards BioProcessing 4.0 and continuous bioprocessing

Burlington, Massachusetts, January 24, 2024 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that the Life Science business sector entered into a non-binding Memorandum of Understanding (MoU) with Mycenax Biotech to explore cooperation to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets. The MoU explores integration of the Life Science business sector’s BioContinuum™ Platform in the entire bioprocessing spectrum for Mycenax’s customers, followed by automation and digitalization of processes.

"Digital transformation in biomanufacturing is creating a paradigm shift towards a bioprocessing facility-of-the-future that is data-intensified, connected and seamless in continuous processing,” said Gladys Wang, Head of Process Solutions, South Asia & Oceania, Life Science business sector of Merck KGaA, Darmstadt, Germany. “By combining the strengths of Life Science business sector and Mycenax in Contract Development and Manufacturing Services, we aim to accelerate the development of new products and process innovations. This will enhance resilience in both research and production.”

As part of the MoU, the Life Science business sector will explore with Mycenax the provision of its extensive support including consultation, technical assistance, and training, ensuring Mycenax receives expert guidance for optimal performance. Recognizing the importance of economic viability, the collaboration will also seek ways to incorporate in-depth cost modelling for better process economics. This strategic analysis aims to enhance cost-effectiveness in next generation bioprocessing.

"Mycenax consistently seeks better solutions and areas for optimization. The integration of continuous processing and Industry 4.0 is not only a future mainstream trend but also possesses the potential for continuous growth," said Pei-Jiun Chen, Ph.D., Chairman/CEO and President of Mycenax. "The collaboration with the Life Science business sector aims to provide innovative continuous processing solutions in the market, to boost our international standing and cater to diverse biopharmaceutical needs."